Astellas Pharma and YASKAWA Establish JV for Cell Therapy Product Manufacturing Platform
Japan-based Astellas Pharma Inc. (TYO: 4503) is set to establish a joint venture (JV) with...
TYO: 4503
Astellas Pharma’s Xospata Wins Regular NMPA Approval for FLT3-Mutated AML
Japan-based Astellas Pharma Inc. (TYO: 4503, OTCMKTS: ALPMY ) announced that the National Medical Products...
Astellas Pharma’s Izervay Gets FDA Approval for GA Treatment Without Dosing Limit
Japan-based Astellas Pharma Inc. (TYO: 4503) has announced that the US Food and Drug Administration...
Astellas Pharma Submits NDA for Avacincaptad Pegol in Japan for Geographic Atrophy
Japan-based major Astellas Pharma (TYO: 4503) announced that it has submitted a New Drug Application...
Astellas’ Padcev and Keytruda Combo Cleared by NMPA for Urothelial Cancer
Japan-based Astellas Pharma Inc. (TYO: 4503) has announced marketing clearance by China’s National Medical Products...
Astellas Pharma’s Vyloy Approved by NMPA for CLDN18.2 Positive Gastric Cancer
China’s National Medical Products Administration (NMPA) has indicated on its website that Japan-based Astellas Pharma...
Astellas Pharma Partners with Axcelead DDP for Targeted Protein Degraders Discovery
Japan-based Astellas Pharma Inc. (TYO: 4503) has struck an accord with compatriot firm Axcelead Drug...
Astellas Pharma Inks Licensing Deal with Sangamo Therapeutics for Neurological AV Capsid STAC-BBB
Japan-based Astellas Pharma Inc. (TYO: 4503) has revealed a strategic licensing agreement with US-based Sangamo...
LaNova Medicines Regains Rights to Claudin 18.2 Targeting ADC LM-302 from BMS
LaNova Medicines Ltd, a Shanghai-based developer of cancer therapies, has announced the reclamation of control...
Astellas Pharma’s Vyloy Receives FDA Approval for Gastric Cancer Treatment in CLDN18.2 Positive Tumors
Astellas Pharma Inc. (TYO: 4503), a Japanese pharmaceutical company, has announced that it has received...
Astellas Pharma’s Vyloy Receives FDA Approval for CLDN18.2 Positive Gastric Cancer Treatment
Astellas Pharma (TYO: 4503) has announced that the U.S. Food and Drug Administration (FDA) has...
Astellas Pharma Employee in China Formally Indicted on Espionage Suspicion
Astellas Pharma Inc., a Japanese pharmaceutical company listed on the Tokyo Stock Exchange (TYO: 4503),...
Astellas Pharma’s Padcev Receives NMPA Approval for Urothelial Cancer Treatment
TOKYO—Astellas Pharma Inc. (TYO: 4503) has announced that its anti-HER3 antibody-drug conjugate (ADC), Padcev (enfortumab...
Astellas Pharma Secures UK Approval for First-in-Class Gastric Cancer Therapy Vyloy
Astellas Pharma (TYO: 4503), a leading Japanese pharmaceutical company, has secured market approval in the...
Pfizer, Astellas, and University of California Sue Qilu Pharma Over Xtandi Patent Infringement
Pfizer Inc. (NYSE: PFE), through its subsidiary Medivation, and co-development partner Astellas Pharma Inc. (TYO:...
Astellas Pharma Reports Robust Q1 FY2024 Results, Highlighting Growth in Core Therapies
Japan-based Astellas Pharma Inc. (TYO: 4503) has announced its financial results for the first quarter...
Astellas Pharma’s Xtandi Secures Third Market Approval in China for Prostate Cancer Treatment
Astellas Pharma Inc. (TYO: 4503), a leading Japanese pharmaceutical company, has announced that it has...
Astellas Resubmits FDA Application for Vyloy as Treatment for CLDN18.2-Positive Cancer
Astellas Pharma Inc. (TYO: 4503), a Japanese pharmaceutical company, has resubmitted its first-in-class anti-CLDN18.2 biologic...
Astellas Pharma Considers Joint Cell Therapy Platform with Yaskawa Electric
Astellas Pharma Inc. (TYO: 4503), a leading Japanese pharmaceutical company, has announced that it is...
Astellas Invests USD 90 Million in New US Facility to Boost Research and Commercialization
Japanese pharmaceutical company Astellas Pharma Inc. (TYO: 4503) has inaugurated a state-of-the-art laboratory and office...